Inflammatory bowel disease symposium

April 2005
Gut;Apr2005 Supplement 2, Vol. 54, pA23
Academic Journal
The article presents information on abstracts related to inflammatory bowel disease. An abstrct focuses on infliximab for the treatment of pyoderma gangrenosum. Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha. In the first randomized placebo controlled trial of any drug for the treatment of PG, researchers have studied of role of infliximab in this disorder.


Related Articles

  • Case study: diagnosis and treatment of pyoderma gangrenosum. Burton, Julie // British Journal of Nursing;9/8/2005, Vol. 14 Issue 16, pS10 

    Pyoderma gangrenosum, is an ulcerative, inflammatory disorder often associated in the field of stoma care with inflammatory bowel disease (IBD) (Lyon and Smith, 2001). Pyoderma gangrenosum is distinctive in that it normally has a purple rolled edge and is extremely painful. The pathogenesis is...

  • 99 mTc antigranulocyte monoclonal antibody imaging for the detection and assessment of inflammatory bowel disease newly diagnosed by colonoscopy in children. Charron, Martin; Di Lorenzo, Carlo; Kocoshis, Samuel A.; Hickeson, Mark P.; Orenstein, Susan R.; Goyal, Alka; Kahn, Seama; Collins, Lori // Pediatric Radiology;Nov2001, Vol. 31 Issue 11, p796 

    Objective: This prospective study evaluated a 99mTc antigranulocyte monoclonal antibody Fab' imaging agent (Sulesomab) in children with inflammatory bowel disease (IBD) newly diagnosed by colonoscopy. Materials and methods: Ten children (4 boys, 6 girls; mean age 14 years) with newly diagnosed...

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...

  • Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. R K Weersma // Gut;Mar2009, Vol. 58 Issue 3, p388 

    BACKGROUND: Crohn’s disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD). METHODS: We studied 2804...

  • Dysbiosis in inflammatory bowel disease. Tamboli C P; Neut C; Desreumaux P; Colombel J F // Gut;Jan2004, Vol. 53 Issue 1, p1 

    Abundant data have incriminated intestinal bacteria in the initiation and amplification stages of inflammatory bowel diseases. However, the precise role of intestinal bacteria remains elusive. One theory has suggested a breakdown in the balance between putative species of "protective" versus...

  • Inflammatory Bowel Disease in Kuwait. Al-Nakib, B.; Radhakrishnan, S.; Jacob, G. S.; Al-Liddawi, H.; Al-Ruwaih, A. // American Journal of Gastroenterology;Mar1984, Vol. 79 Issue 3, p191 

    Inflammatory bowel disease is considered to be rare or nonexistent in some Arab countries. During a period of 6 years, 91 patients with ulcerative colitis and 17 with Crohn's disease were seen for initial diagnosis in the Gastroenterology Department of Amiri Hospital, which serves 55% of the...

  • Clinical treatment options for peristomal pyoderma gangrenosum. Vujnovich, Angela // British Journal of Nursing;9/8/2005, Vol. 14 Issue 16, pS4 

    Pyoderma gangrenosum is a rare debilitating skin disease of unknown aetiology that manifests itself as painful lesions and is often associated with inflammatory bowel disease. Stoma care nurses will encounter it directly around the stoma as peristomal pyoderma gangrenosum (PPG). There are many...

  • COMPANY SPOTLIGHT -- Centocor.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p49 

    The article presents information on the pharmaceutical company Centocor Inc. Centocor has announced that the United States Food and Drug Administration has given its final approval for Remicade, a therapy for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. Remicade has...

  • CITATIONS AND CLINICIANS' NOTES: INFLAMMATORY BOWEL DISEASE.  // Current Medical Literature: Gastroenterology;2004, Vol. 23 Issue 1, p22 

    Examines the use of infliximab by researchers from Pittsburgh, Pennsylvania. Association of inflammatory bowel disease with the development of pyoderma gangrenosum; Use of the agent in treating pyoderma gangrenosum; Safety and efficacy of the use of the chimeric monoclonal antibody.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics